Synthesis and pharmacological activity of pyrazolopyrrolopyrimidine derivatives having vasorelaxing activity.

Drug design and discovery Pub Date : 1999-08-01
T Kumagai, H Matsunaga, S Kaneda, H Shimizu, E Ebisawa, M Kitamura, T Suzuki, M Yuasa, Y Nagao
{"title":"Synthesis and pharmacological activity of pyrazolopyrrolopyrimidine derivatives having vasorelaxing activity.","authors":"T Kumagai,&nbsp;H Matsunaga,&nbsp;S Kaneda,&nbsp;H Shimizu,&nbsp;E Ebisawa,&nbsp;M Kitamura,&nbsp;T Suzuki,&nbsp;M Yuasa,&nbsp;Y Nagao","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A new series of 5-substituted and 5-nonsubstituted pyrazolopyrrolopyrimidine derivatives were synthesized, and their vasorelaxing and hypotensive activities were evaluated. The syntheses were efficiently accomplished through the use of three key intermediates (7, 16, and 24), as shown in Schemes I-III. The desired pharmacological activities were confirmed on the basis of vasorelaxing activity in rat aorta (in vitro) and hypotensive activity in rats (in vivo). Specifically, compound 25 exhibited the strongest activity and appears to be a promising clinical lead for the development of a new antihypertensive agent.</p>","PeriodicalId":11297,"journal":{"name":"Drug design and discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug design and discovery","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A new series of 5-substituted and 5-nonsubstituted pyrazolopyrrolopyrimidine derivatives were synthesized, and their vasorelaxing and hypotensive activities were evaluated. The syntheses were efficiently accomplished through the use of three key intermediates (7, 16, and 24), as shown in Schemes I-III. The desired pharmacological activities were confirmed on the basis of vasorelaxing activity in rat aorta (in vitro) and hypotensive activity in rats (in vivo). Specifically, compound 25 exhibited the strongest activity and appears to be a promising clinical lead for the development of a new antihypertensive agent.

具有血管舒张活性的吡唑吡喃嘧啶衍生物的合成及药理活性。
合成了一系列新的5-取代和5-非取代吡唑吡喃嘧啶衍生物,并对其血管舒张和降压活性进行了评价。通过使用三个关键中间体(7,16和24),如方案I-III所示,有效地完成了合成。通过对大鼠主动脉的血管舒张活性(体外)和对大鼠的降血压活性(体内)来确定预期的药理活性。具体而言,化合物25表现出最强的活性,似乎是一种新的抗高血压药物开发的有希望的临床先导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信